Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals reported its Q1 FY26 results on August 7, 2025. Total income grew 7.4% year-on-year to ₹169.34 crore, while revenue from operations rose to ₹154.07 crore from ₹147.28 crore. Net profit jumped 16.9% to ₹27.70 crore compared to ₹23.69 crore in the same quarter last year. EBITDA rose 17.9% to ₹39.08 crore, indicating margin expansion. EPS stood at ₹13.82 versus ₹11.82 in Q1 FY25. The board also approved the re-appointment of the Managing Director and three Whole-Time Directors for five-year terms and appointed a new Secretarial Auditor for FY26-FY30.
Strong Q1 performance with healthy profit growth and EBITDA margin improvement signals operational strength. The company has zero-term debt and is targeting ₹1,000 crore revenue in 3 years, with FII holding rising to 5.13%. Positive for shareholders, though revenue growth remains in single digits versus the 15-18% annual target.